MedTrace Logo

Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences

NCT05576922 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-04-10

No results posted yet for this study

Summary

The study aims at comparing two different approaches for the treatment of implant esthetic complications (peri-implant soft tissue dehiscences): autogenous connective tissue graft vs collagen matrix + recombinant human platelet derived growth factor-BB

Conditions

  • Implant Complication

Interventions

OTHER

Prosthetic-surgical approach + autogenous graft

Coronally advanced flap with an autogenous graft (CTG)

OTHER

Prosthetic-surgical approach + graft substitute

Coronally advanced flap with a graft substitute (collagen matrix and rhPDGF-BB)

Sponsors & Collaborators

  • Harvard Medical School (HMS and HSDM)

    lead OTHER

Principal Investigators

  • Lorenzo Tavelli, DDS, MS · Harvard School of Dental Medicine, Boston, USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-04
Primary Completion
2025-10-20
Completion
2025-10-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05576922 on ClinicalTrials.gov